Systemic Biomarkers and Unique Pathways in Different Phenotypes of Heart Failure with Preserved Ejection Fraction
Hao Chen,
Milorad Tesic,
Valentina N. Nikolic,
Milan Pavlovic,
Rada M. Vucic,
Ana Spasic,
Hristina Jovanovic,
Ivana Jovanovic,
Stephanie E. L. Town,
Matthew P. Padula,
Lana McClements
Affiliations
Hao Chen
School of Life Sciences & Institute for Biomedical Materials and Devices, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia
Milorad Tesic
Clinic for Cardiology, University Clinical Center of Serbia, 11000 Belgrade, Serbia
Valentina N. Nikolic
Faculty of Medicine, Department of Pharmacology and Toxicology, University of Nis, 18000 Nis, Serbia
Milan Pavlovic
Faculty of Medicine, Department of Internal Medicine—Cardiology, University of Nis, 18000 Nis, Serbia
Rada M. Vucic
Faculty of Medical Sciences, Department of Internal Medicine, University of Kragujevac, 34000 Kragujevac, Serbia
Ana Spasic
Faculty of Medicine, Department of Pharmacology and Toxicology, University of Nis, 18000 Nis, Serbia
Hristina Jovanovic
Faculty of Medicine, Department of Pharmacology and Toxicology, University of Nis, 18000 Nis, Serbia
Ivana Jovanovic
Clinic for Cardiology, University Clinical Center of Serbia, 11000 Belgrade, Serbia
Stephanie E. L. Town
School of Life Sciences & Institute for Biomedical Materials and Devices, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia
Matthew P. Padula
School of Life Sciences & Institute for Biomedical Materials and Devices, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia
Lana McClements
School of Life Sciences & Institute for Biomedical Materials and Devices, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia
Heart failure with preserved ejection fraction (HFpEF) accounts for around 50% of all heart failure cases. It is a heterogeneous condition with poorly understood pathogenesis. Here, we aimed to identify unique pathogenic mechanisms in acute and chronic HFpEF and hypertrophic cardiomyopathy (HCM). We performed unbiased, comprehensive proteomic analyses of plasma samples from gender- and BMI-matched patients with acute HFpEF (n = 8), chronic HFpEF (n = 9) and HCM (n = 14) using liquid chromatography–mass spectrometry. Distinct molecular signatures were observed in different HFpEF forms. Clusters of biomarkers differentially abundant between HFpEF forms were predominantly associated with microvascular inflammation. New candidate protein markers were also identified, including leucine-rich alpha-2-glycoprotein 1 (LRG1), serum amyloid A1 (SAA1) and inter-alpha-trypsin inhibitor heavy chain 3 (ITIH3). Our study is the first to apply systematic, quantitative proteomic screening of plasma samples from patients with different subtypes of HFpEF and identify candidate biomarkers for improved management of acute and chronic HFpEF and HCM.
